Accelerating norovirus vaccine development

Integra Biosciences has contributed to HilleVax's pioneering research on norovirus vaccine development by awarding 50 EVOLVE manual pipettes, GRIPTIPS® pipette tips valued at US $1000, and various lab accessories. The award, part of the recent 'Integra supports start-ups' competition concluding in April 2023, will empower HilleVax in accelerating the development of its norovirus vaccine candidate towards licensure.

HilleVax, founded to address health inequalities through novel vaccines, is a collaborative venture between Frazier Healthcare and Takeda. Focused on advancing the promising Phase II clinical trials of HIL-214, a virus-like particle vaccine for norovirus, the company is in the process of establishing its laboratory. Winning the 'Integra supports start-ups' competition comes as a significant boost for HilleVax.

Dr Erika Olson, Senior Scientist in the company's Clinical Assay Group, expressed her enthusiasm: "I have always had great experiences working with Integra products in the past; the pipettes are ergonomic, easy to program, and work beautifully every time. Having access to a broad pipetting volume range will help ensure that we obtain the highest efficiency and quality of results, and the GRIPTIPS give us confidence that the tips are securely attached. In addition, the ability of EVOLVE pipettes to switch from the lowest to the highest volume in just a few clicks is a very unique aspect that – along with the lightweight design and low tip attachment and ejection forces – significantly improves ergonomics to reduce repetitive strain injuries. We are really excited to get started and put the pipettes to work."

More information online